Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

Neurocrine Biosciences: Clinical Trials & FDA Approval Profile

Neurocrine Biosciences (San Diego, CA) sponsors 46 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 19 active protocols (14 recruiting now), 17 completed protocols, and 4 all-time original FDA Drugs@FDA NDA and BLA approvals.

Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)21.7%
Median Closed Enrollment vs National (145 pts)81 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for Neurocrine Biosciences
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)46
Active Pipeline (Recruiting Now)19 (14)
Completed vs Stopped Early17 / 10 (21.7%)
Median Closed Actual Enrollment81 participants
Physical Hospital Site Disclosure97.6% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals4 (3 since 2018)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Neurocrine Biosciences across sibling Meru public-data platforms.

Explore interactive annual charts and M&A subsidiary rollups in the Neurocrine Biosciences Interactive Dossier, benchmark peers in Neurology, Psychiatry, and Pain, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI